Novartis AG ADR
USUSDNovartis AG ADR (SW:NOVNEE) — Drug Manufacturers - General. Počet burz, na kterých se obchodují akcie společnosti: 6. Na této stránce — cena a graf, dividendy, největší akcionáři a historie počtu akcií.
O společnosti
- Web
- novartis.com
- Sektor
- Healthcare · Drug Manufacturers - General
- Sídlo
- BASEL, Switzerland
- Generální ředitel
- Dr. Vasant Narasimhan M.D.
- Zaměstnanci
- 75 267
- Založena
- 1996
- Akcie v oběhu
- 1.91 mld. k 2025-12-31
- Volně obchodovatelné akcie
- 1.86 mld.
- Tržní kapitalizace
- 276.48 mld. USD
- Insideři
- 0.01%
- Instituce
- 7.27%
- Odvětví (SIC)
- Pharmaceutical Preparations
- Právní forma
- MVII
- ISIN
- CH0012005267
- LEI
- 5493007HIVTX6SY6XD66
- Výplatní poměr
- 71.1%
- FCF
- 15.0 mld. USD61%
- Dluh
- 49.0 mld. USD2.6 r. FCF
- Dividendová řada
- 20 r.
Popis
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Burzy a tickery
| Burza | Ticker | Měna | Cena | Typ |
|---|---|---|---|---|
| US USA Stocks | NVSEF | USD | 134.22 -0.23% | kmenové akcie |
| MI Borsa Italiana (Milan) | 1NOVN | EUR | 125.16 +0.21% | kmenové akcie |
| SW SIX Swiss Exchange | NOVN | CHF | 119.8 -0.13% | kmenové akcie |
| SW SIX Swiss Exchange | NOVNEE | CHF | 120.02 -1.80% | kmenové akcie |
| VI Vienna Stock Exchange | NOVN | EUR | 126.72 | kmenové akcie |
| XETRA Xetra | NOT | EUR | 126.82 +0.48% | kmenové akcie |
Dividendy
Novartis AG ADR (NVSEF) vyplácí dividendy nepravidelně. Za posledních 12 měsíců bylo vyplaceno 3.7 CHF na akcii (platby: 1). Na základě platební historie se očekává další datum ex-dividendy kolem 11.03.2027. Roky nepřerušených dividend: 20.
| Ex-dividendový den | Výplata | Částka | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-03-11 | 2026-03-12 | 3.7000 CHF | 3.3/3.3 % | roční | US:NVSEF |
Zprávy tento týden
Zatím žádné zprávy z webu společnosti.
Největší držitelé
| Držitel | Podíl | Akcie | Datum zprávy |
|---|---|---|---|
| Fisher Asset Management,… | 0.76% | 15.52 mil. | 2026-06-30 |
| Morgan Stanley | 0.43% | 8.73 mil. | 2026-06-30 |
| Dimensional Fund Advisor… | 0.4% | 8.12 mil. | 2026-06-30 |
| Primecap Management Comp… | 0.32% | 6.59 mil. | 2026-06-30 |
| LOOMIS SAYLES & CO L P | 0.26% | 5.24 mil. | 2026-06-30 |
| Bank of America Corporat… | 0.24% | 4.91 mil. | 2026-06-30 |
| VANGUARD CHESTER FUNDS-V… | 0.21% | 4.25 mil. | 2026-06-30 |
| Franklin Resources, Inc. | 0.16% | 3.25 mil. | 2026-06-30 |
| Blackrock Inc. | 0.15% | 3.05 mil. | 2026-06-30 |
| Goldman Sachs Group Inc | 0.15% | 2.98 mil. | 2026-06-30 |
| Northern Trust Corporati… | 0.14% | 2.79 mil. | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.11% | 2.14 mil. | 2026-04-30 |
| LOOMIS SAYLES FUNDS II-L… | 0.07% | 1.42 mil. | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.06% | 1.21 mil. | 2026-06-30 |
| Franklin Mutual Series F… | 0.06% | 1.19 mil. | 2026-06-30 |
| JANUS INVESTMENT FUND-Ja… | 0.05% | 949 726 | 2026-06-30 |
| Principal Funds, Inc-Equ… | 0.05% | 945 091 | 2026-04-30 |
| Dimensional ETF Trust-Di… | 0.04% | 888 855 | 2026-04-30 |
| Franklin Mutual Series F… | 0.04% | 812 618 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.04% | 716 836 | 2026-04-30 |
Události u regulátora
| Datum | Regulátor | Událost | Podrobnosti |
|---|---|---|---|
| 2026-10-02 | ESMA | оновлення даних інструмента | ISIN, майданчик HAND |
